Project Grant HT94252410683

Federal Grant Award Summary Seattle Children's Research Institute received a $434,361 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. The award funds the development of a multispecific T cell engaging (MTE) therapy targeting mixed-phenotype acute leukemia (MPAL), a high-risk leukemia subtype that presents with both myeloid and lymphoid surface antigens. This research addresses a...

Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $456,414 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2025, through April 30, 2030. This award supports the clinical development and evaluation of B7-H3 Chimeric Antigen Receptor (CAR) T cell therapy for children and young adults with Diffuse Intrinsic Pontine Glioma (DIPG), a fatal...

This Project Grant award of $719,882.00, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research initiative at the University of California, San Francisco aimed at elucidating pulmonary immune pathways that drive lung injury following pediatric hematopoietic cell transplantation (HCT). The project, which commenced on August 20, 2025, and extends through May 31, 2030, will deliver research products...

This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...

The Department of Defense's Defense Health Agency awarded a $3,188,604 Project Grant titled "USE OF HIGH-THROUGHPUT SEQUENCING OF THE IMMUNOGLOBULIN LOCI FOR REFINED RISK STRATIFICATION IN PEDIATRIC B-ALL" to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. This grant, funded through the Military Medical Research and Development (CFDA 12.420) program, supports biomedical research related to military medicine, with a focus on cancer, neurological...

Federal Project Grant Award Summary Boston Children's Hospital received a $178,000 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on June 15, 2025, with completion scheduled for June 14, 2026. The grant supports the development of a bone marrow organoid system to study RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy (RUNX1-FPD/MM), a rare genetic disorder characterized by germline heterozygous loss-of-function...

This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $734,435.00 in funding to the Beckman Research Institute of the City of Hope to conduct research aimed at overcoming resistance to BH3 mimetic drugs in the treatment of acute myeloid leukemia (AML), particularly in older patients. The key objectives are to define the molecular mechanisms underlying BH3 mimetic resistance in AML and evaluate whether targeting the ADSS2 enzyme,...

The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate...

This federal Project Grant award of $225,101 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the mechanisms underlying the increased risk of hematological malignancies in sickle cell disease patients. The key objectives of this 2-year project are to: 1) Perform experiments to understand how increased oxidative stress and DNA damage in hematopoietic stem and progenitor cells lead to the development of clonal...